Loading...
Loading...
CLDX| Name | Value |
|---|---|
| Revenues | 4.1M |
| Cost of Revenue | 0.8M |
| Gross Profit | 3.4M |
| Operating Expense | 38.5M |
| Operating I/L | -35.1M |
| Other Income/Expense | 4.3M |
| Interest Income | 4.3M |
| Pretax | -43.3M |
| Income Tax Expense | 13.4M |
| Net Income/Loss | -43.3M |
Celldex Therapeutics, Inc. is a biopharmaceutical company specializing in the development of therapeutic monoclonal and bispecific antibodies for the treatment of inflammatory diseases and various forms of cancer. The company's drug candidates, including CDX-0159, CDX-1140, and CDX-527, target receptor tyrosine kinase KIT, CD40, and the PD-L1/PD-1 pathway, respectively, to activate immune responses and inhibit tumor growth. Celldex generates revenue through the clinical development and potential commercialization of these antibody-based therapeutics, as well as through research collaborations and license agreements with institutions and companies such as University of Southampton, Amgen Inc., and Yale University.
